natgillin/translations-raw huggingface dataset:
No information is available on the use of the vaccine in animals with maternally derived antibodies. 
Na voljo ni nobenih informacij o uporabi cepiva pri živalih z maternalnimi protitelesi.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 05/08/2011 
Datum pridobitve dovoljenja za promet: 05/08/2011 Datum zadnjega podaljšanja dovoljenja za promet: 18/04/2016
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP. Once broached use immediately. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini po {EXP}.Načeto uporabite takoj.
According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of the immunological veterinary medicinal products on the whole or part of their territory if it is established that: 
Skladno z 71. členom Direktive 2001/82/ES Evropskega parlamenta in Sveta, z vsemi dopolnitvami in spremembami lahko država članica, skladno z nacionalno zakonodajo, prepove izdelavo, uvoz/vnos,
A slight to moderate increase of local reactions may commonly be observed after a 2-fold overdose lasting for a maximum of 56 days. 
Pri 2-krat prevelikem odmerku se lahko pogosto opazi blago do zmerno povečanje lokalnih reakcij, ki trajajo največ 56 dni.
Duration of immunity: 12 months after completion of the primary vaccination course. 
Trajanje imunosti: 12 mesecev po končanem osnovnem cepljenju.
Potassium dihydrogen phosphate Disodium hydrogen phosphate dodecahydrate Sodium chloride 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi aluminijev hidroksid saponin tiomersal kalijev klorid kalijev dihidrogenfosfat natrijev hidrogenfosfat dodekahidrat natrijev klorid
PACKAGE LEAFLET: Zulvac1 Bovis suspension for injection for cattle 
NAVODILO ZA UPORABO Zulvac 1 Bovis suspenzija za injiciranje za govedo
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Outer carton 1 x 20ml, 1 x 100ml and 1 x 240ml 
PODATKI NA ZUNANJI OVOJNINI Kartonska škatla 1 x 20 ml, 1 x 100 ml in 1 x 240 ml
Onset of immunity: 15 days after completion of the primary vaccination scheme. 
Nastop imunosti: 15 dni po osnovnem programu cepljenja.
For active immunisation of cattle from 2 and a half months of age for the prevention* of viraemia caused by Bluetongue Virus (BTV), serotypes 1. 
Za aktivno imunizacijo goveda, starejšega od 2 in pol meseca starosti, za preprečitev* viremije, ki jo povzroča virus bolezni modrikastega jezika, serotip 1.
EXPIRY DATE EXP {month/year} Once broached use immediately. 
EXP {mesec/leto} Načeto uporabite takoj.
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 
inaktiviran virus bolezni modrikastega jezika, serotip 1, sev BTV-1/ALG2006/01 E1 RP*≥1
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 Aluminium hydroxide, saponin and thiomersal. 
V odmerku 2 ml: inaktiviran virus bolezni modrikastega jezika, serotip 1, sev BTV-1/ALG2006/01 E1, aluminijev hidroksid, saponin in tiomersal.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Vial label 100 ml and 240ml 
PODATKI NA STIČNI OZ. PRIMARNI OVOJNINI Nalepka na viali 100 ml in 240 ml
Zero days. 
KARENCA Karenca: nič dni.
After administration of a two-fold overdose, a rectal temperature increase up to 2.1 ºC may occur 1 day after the injection and then rectal temperatures return to normal values. 
Po dajanju dvojnega odmerka se lahko 1 dan po injiciranju pojavi povišanje rektalne temperature do 2,1°C.
ATCvet code: QI02AA08 To stimulate active immunity against Bluetongue Virus, serotype 1 in cattle. 
Za stimulacijo aktivne imunosti proti virusu bolezni modrikastega jezika, serotip 1, pri govedu.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial label 20ml 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Vaccinate only healthy animals. 
POSEBNO(A) OPOZORILO(A) Cepite samo zdrave živali.
After first vaccination a rectal temperature increase of up to 1.6°C may occur very commonly the 3rd day after the injection. 
Zelo pogosto se tretji dan po prvem cepljenju lahko pojavi povišanje rektalne temperature, ki ne presega 1,6 °C.
After second and third vaccination a rectal temperature increase of up to 1.3°C and 2.8°C respectively may occur very commonly one day after the injection and then rectal temperatures return to normal values. 
Zelo pogosto se en dan po injiciranju se lahko pojavi povišanje rektalne temperature, ki ne presega 1,3 °C (po drugem cepljenju) oziroma 2,8 °C (po tretjem cepljenju).
STATEMENT OF ACTIVE SUBSTANCES Per dose of 2 ml 
NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA ( MRL)
RP* ≥ 1 
Rp-Vet..
The recommended dose of Stocrin for adults is 600 mg once a day. 
Priporočeni odmerek zdravila Stocrin za odrasle je 600 mg enkrat na dan.
The European Commission granted a marketing authorisation valid throughout the European Union for Stocrin on 28 May 1999. 
Evropska komisija je dovoljenje za promet z zdravilom Stocrin, veljavno po vsej Evropski uniji, izdala 28. maja 1999.
What measures are being taken to ensure the safe and effective use of Stocrin? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Stocrin?
Other information about Stocrin 
Druge informacije o zdravilu Stocrin
The full EPAR for Stocrin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Stocrin je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Stocrin. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Stocrin.
In patients aged 3 to 17 years, the dose depends on body weight. 
Pri bolnikih, starih od treh do 17 let, je količina odmerka odvisna od njihove telesne mase.
What is Stocrin and what is it used for? 
Kaj je zdravilo Stocrin in za kaj se uporablja?
Stocrin must not be used in patients with severe liver disease. 
Zdravila Stocrin ne smejo uporabljati bolniki z resnimi boleznimi jeter.
It is recommended that Stocrin be taken on an empty stomach and without food, preferably at bedtime. 
Priporočljivo je, da se zdravilo Stocrin jemlje na prazen želodec in brez hrane, po možnosti pred spanjem.
What benefits of Stocrin have been shown in studies? 
Kakšne koristi je zdravilo Stocrin izkazalo v študijah?
What are the risks associated with Stocrin? 
Kakšna tveganja so povezana z zdravilom Stocrin?
Stocrin must be avoided if patients are taking certain medicines because it can increase their side effects or reduce their effectiveness, or because the combination may increase effects on the heart. 
Uporabi zdravila Stocrin se je treba izogibati, če bolniki jemljejo določena zdravila, saj lahko okrepi njihove neželene učinke ali zmanjša njihovo učinkovitost ali pa kombinacija z njimi lahko okrepi učinke na srce.
Stocrin can affect the electrical activity of the heart and so must also not be used in patients with heart problems such as changes in heart rhythm and activity, slow heart rate or heart failure or other conditions that can affect the heart's electrical activity, or who have close relatives that have died suddenly from a heart condition or were born with heart problems. 
Zdravilo Stocrin lahko vpliva na električno dejavnost srca in se zato ne sme uporabljati pri bolnikih s težavami s srcem, kot so spremembe srčnega ritma in aktivnosti, nizek srčni utrip, srčno popuščanje ali druge bolezni, ki lahko vplivajo na električno dejavnost srca, ali pri bolnikih, katerih bližnji sorodnik je nenadoma umrl zaradi bolezni srca ali pa ima prirojene težave s srcem.
It is not intended to provide practical advice on how to use Stocrin. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Stocrin has shown benefit in controlling HIV infection in three main studies involving over 1,100 adults. 
Zdravilo Stocrin je pri obvladovanju okužbe z virusom HIV izkazalo koristi v treh glavnih študijah, v katere je bilo vključenih več kot 1 100 odraslih.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Stocrin have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Stocrin upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Why is Stocrin approved? 
Zakaj je bilo zdravilo Stocrin odobreno?
It also noted that there is little information on the benefits of treatment that includes a protease inhibitor in patients who have been treated with Stocrin in the past but which stopped working, although there is no evidence to suggest that protease inhibitors may not work in these patients. 
Poudarila je tudi, da je malo informacij o koristih zdravljenja z zaviralcem proteaze pri bolnikih, ki so bili v preteklosti zdravljeni z zdravilom Stocrin, ki je prenehalo biti učinkovito, čeprav ni dokazov, da zaviralci proteaze pri teh bolnikih ne bi bili učinkoviti.
The European Medicines Agency decided that Stocrin's benefits are greater than its risks in antiviral combination treatment of HIV-infected adults, adolescents, and children three years of age and older and recommended that it be approved for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Stocrin večje od z njim povezanih tveganj pri kombiniranem protivirusnem zdravljenju odraslih, mladostnikov in otrok, starih tri leta ali več, ki so okuženi z virusom HIV, in priporočila, da se odobri za uporabo v EU.
By blocking this enzyme, Stocrin, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level. 
Zdravilo Stocrin z zaviranjem tega encima v kombinaciji z drugimi protivirusnimi zdravili zniža količino virusa HIV v krvi in jo ohranja na nizki ravni.
Stocrin does not cure HIV infection or AIDS, but it can hold off damage to the immune system and avoid the development of infections and diseases associated with AIDS. 
Zdravilo Stocrin ne ozdravi okužbe z virusom HIV ali aidsa, vendar pa lahko upočasni slabšanje imunskega sistema ter prepreči razvoj okužb in bolezni, povezanih z aidsom.
Similar results were seen in a study in 57 children aged between 3 and 16 years, given Stocrin in combination with nelfinavir and other antiviral medicines. 
Podobne rezultate so ugotovili v študiji, ki je vključevala 57 otrok, starih med tri in 16 let, ki so prejemali zdravilo Stocrin v kombinaciji z nelfinavirjem in drugimi protivirusnimi zdravili.
The active substance in Stocrin, efavirenz, is a non-nucleoside reverse transcriptase inhibitor (NNRTI). 
Zdravilna učinkovina zdravila Stocrin, efavirenz, je nenukleozidni zaviralec reverzne transkriptaze (NNRTI).
Taking Stocrin with food may lead to an increase in the frequency of side effects. 
Jemanje zdravila Stocrin skupaj s hrano lahko poveča pogostnost neželenih učinkov.
It is available as capsules, tablets and oral solution and must be given in combination with other antiviral medicines. 
Na voljo je v obliki kapsul, tablet in peroralne raztopine, dajati pa ga je treba skupaj z drugimi protivirusnimi zdravili.
Stocrin is an antiviral medicine that is used together with other antiviral medicines to treat patients aged three years or older infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). 
Zdravilo Stocrin je protivirusno zdravilo, ki se uporablja v kombinaciji z drugimi protivirusnimi zdravili za zdravljenje bolnikov, starejših od treh let, ki so okuženi z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
The Stocrin combination was more effective than the combination without Stocrin: 70% and 30% of the patients, respectively, had viral loads below 500 copies/ml after 48 weeks; 
Kombinacija z zdravilom Stocrin je bila učinkovitejša od kombinacije brez njega: 70 % oziroma 30 % bolnikov je imelo po 48 tednih virusno breme nižje od 500 kopij/ml;
The most common side effect with Stocrin (seen in more than 1 patient in 10) is rash. 
Najpogostejši neželeni učinek zdravila Stocrin (ki se je pojavil pri več kot 1 bolniku od 10) je izpuščaj.
For patients who are unable to swallow the capsules or tablets, Stocrin can be given using the oral solution. 
Pri bolnikih, ki ne morejo pogoltniti kapsul ali tablet, se zdravilo Stocrin lahko daje v obliki peroralne raztopine.
Stocrin can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection. 
Predpisovanje in izdaja zdravila Stocrin je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z obvladovanjem okužbe z virusom HIV.
For more information about treatment with Stocrin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Stocrin preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
In all of the studies, the main measure of effectiveness was the number of patients with undetectable levels of HIV-1 in their blood (viral loads) after 24 or 48 weeks of treatment: 
V vseh študijah je bilo glavno merilo učinkovitosti število bolnikov, ki so imeli po 24 ali 48 tednih zdravljenja v krvi nezaznavno raven virusa HIV-1 (virusno breme):
Stocrin is also commonly associated with dizziness, headache, nausea (feeling sick) and tiredness. 
Zdravilo Stocrin pogosto povezujejo tudi z omotico, glavobolom, navzejo (siljenjem na bruhanje) in utrujenostjo.
For practical information about using Stocrin, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Stocrin naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The Agency noted that Stocrin has not been studied adequately in patients with advanced disease (CD4 cell counts below 50 cells/mm3) or after treatment with protease inhibitors (another type of antiviral medicine) that was not working. 
Ugotovila je, da zdravilo Stocrin ni bilo ustrezno raziskano pri bolnikih z napredovalo boleznijo (številom celic CD4, nižjim od 50 celic/mm3) ali po zdravljenju z zaviralci proteaze (drugo vrsto protivirusnega zdravila), ki ni bilo uspešno.
• in the first study, Stocrin in combination with lamivudine and zidovudine or with indinavir (other antiviral medicines) was compared with the combination of indinavir, lamivudine and zidovudine. 
• v prvi študiji so zdravilo Stocrin v kombinaciji z lamivudinom in zidovudinom ali z indinavirjem (drugimi protivirusnimi zdravili) primerjali s kombinacijo indinavirja, lamivudina in zidovudina.
67% of the adults treated with Stocrin in combination with zidovudine and lamivudine had viral loads below 400 copies/ml after 48 weeks, compared with 54% of the patients treated with Stocrin and indinavir, and 45% of the patients treated with indinavir, lamivudine and zidovudine; 
Prva študija je pokazala, da je imelo po 48 tednih virusno breme nižje od 400 kopij/ml 67 % odraslih, zdravljenih z zdravilom Stocrin v kombinaciji z zidovudinom in lamivudinom, 54 % bolnikov, zdravljenih z zdravilom Stocrin in indinavirjem, ter 45 % bolnikov, zdravljenih z indinavirjem, lamivudinom in zidovudinom;
How does Stocrin work? 
Kako zdravilo Stocrin deluje?
For the full list of side effects reported with Stocrin, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Stocrin, glejte navodilo za uporabo.
• the third study compared adding Stocrin or placebo (a dummy treatment) to a combination of antiviral medicines that included indinavir and two other antiviral medicines, in patients who had already been receiving treatment for HIV infection. 
• v tretji študiji so primerjali dodajanje zdravila Stocrin ali placeba (zdravila brez zdravilne učinkovine) kombinaciji protivirusnih zdravil, ki je vključevala indinavir in dve drugi protivirusni zdravili, pri bolnikih, ki so se že zdravili zaradi okužbe z virusom HIV.
How is Stocrin used? 
Kako se zdravilo Stocrin uporablja?
• the second study compared Stocrin in combination with nelfinavir and two other antiviral medicines with the same combination without Stocrin. 
• v drugi študiji so zdravilo Stocrin v kombinaciji z nelfinavirjem in dvema drugima protivirusnima zdraviloma primerjali z enako kombinacijo, vendar brez zdravila Stocrin.
The dose of Stocrin may need to be adjusted in patients taking certain other medicines at the same time. 
Poleg tega je pri sočasnem jemanju določenih drugih zdravil včasih treba prilagoditi odmerek zdravila Stocrin.
More patients receiving Stocrin had viral loads below 400 copies/ml than those taking placebo after 24 weeks 
Tretja študija je pokazala, da je imelo po 24 tednih virusno breme nižje od 400 kopij/ml več bolnikov, ki so prejemali zdravilo Stocrin, kot bolnikov, ki so prejemali placebo.
To investigate this further the Agency recommended that a study be carried out. 
Da bi to vprašanje nadalje proučili, priporoča, da se izvede študija.
Further information on Laventair Ellipta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Nadaljnje informacije o zdravilu Laventair Ellipta so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Recommendations and precautions to be followed by healthcare professionals and patients have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
In all 4 studies, involving over 4,700 patients, the main measure of effectiveness was based on changes in the patients' forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second). 
V vseh štirih študijah, v katerih je sodelovalo več kot 4 700 bolnikov, je bilo glavno merilo učinkovitosti sprememba bolnikovega forsiranega ekspiracijskega volumna (FEV1 - največja količina zraka, ki jo oseba lahko izdihne v eni sekundi).
For detailed information on using the inhaler correctly, see the instructions in the package leaflet or contact your doctor and pharmacist. 
Za podrobnejše informacije o pravilni uporabi inhalatorja glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
As medicines of the same class as Laventair Ellipta may have an effect on the heart and blood vessels in the brain, the company that markets the medicine will carry out a long-term study in patients to collect further information on its safety in comparison with tiotropium. 
Ker lahko zdravila istega razreda kot zdravilo Laventair Ellipta vplivajo na srce in krvne žile v možganih, bo podjetje, ki trži zdravilo, izvedlo dolgoročno študijo pri bolnikih, da bo zbralo dodatne informacije o njegovi varnosti v primerjavi s tiotropijem.
Previously known as Laventair. 
Predhodno znano kot zdravilo Laventair.
The most common side effects with Laventair Ellipta (which may affect up to 1 in 10 people) are upper respiratory tract infections (nose and throat infection), urinary tract infections (infection of the structures that carry urine), pharyngitis (inflammation of the throat), sinusitis (inflammation of the sinuses), nasopharyngitis (inflammation of the nose and throat), headache, cough, oropharyngeal pain (pain in the mouth and throat), constipation and dry mouth. 
Najpogostejši neželeni učinki zdravila Laventair Ellipta (ki se lahko pojavijo pri največ 1 bolniku od 10) so okužbe zgornjih dihal (okužbe nosu in žrela), okužbe sečil (okužbe struktur za odvajanje urina), faringitis (vnetje žrela), sinuzitis (vnetje sinusov), nazofaringitis (vnetje nosu in žrela), glavobol, kašelj, orofaringealna bolečina (bolečina v ustih in žrelu), zaprtje in suha usta.
Laventair Ellipta1 (umeclidinium bromide / vilanterol) 
Laventair Ellipta1 (umeklidinijev bromid/vilanterol)
Laventair Ellipta received a marketing authorisation valid throughout the EU on 8 May 2014. 
Za zdravilo Laventair Ellipta je bilo 8. maja 2014 izdano dovoljenje za promet, veljavno po vsej EU.
What measures are being taken to ensure the safe and effective use of Laventair Ellipta? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Laventair Ellipta?
The European Medicines Agency decided that Laventair Ellipta's benefits are greater than its risks and recommended that it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Laventair Ellipta večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Side effects reported with Laventair Ellipta are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Laventair Ellipta, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
The Agency also noted that there were no major safety concerns with Laventair Ellipta, with side effects being manageable, although the longterm safety data so far are limited. 
Ugotovila je tudi, da ni večjih pomislekov glede varnosti zdravila Laventair Ellipta, saj so njegovi neželeni učinki obvladljivi, čeprav so podatki o dolgoročni varnosti zdravila trenutno omejeni.
As for all medicines, data on the use of Laventair Ellipta are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Laventair Ellipta stalno spremljajo.
It works by attaching to beta-2 receptors found in the muscle cells of many organs including the airways in the lungs. 
Deluje tako, da se veže na receptorje beta2, ki so v mišičnih celicah številnih organov, vključno z dihalnimi potmi v pljučih.
Laventair Ellipta is used for maintenance (regular) treatment. 
Zdravilo Laventair Ellipta se uporablja za vzdrževalno (redno) zdravljenje.
The combined action of the two active substances helps to keep the airways open and allows the patient to breathe more easily. 
Kombinirano delovanje obeh učinkovin pomaga ohranjati dihalne poti prehodne in bolniku olajša dihanje.
It works by blocking other receptors called muscarinic receptors, which control the contraction of muscles. 
Deluje tako, da zavira druge receptorje, imenovane muskarinski receptorji, ki nadzorujejo krčenje mišic.
Each inhalation provides 65 micrograms of umeclidinium bromide (equivalent to 55 micrograms of umeclidinium) and 22 micrograms of vilanterol. 
Z enim vdihom se dovede 65 mikrogramov umeklidinijevega bromida (kar je enakovredno 55 mikrogramom umeklidinija) in 22 mikrogramov vilanterola.
Other information about Laventair Ellipta 
Druge informacije o zdravilu Laventair Ellipta
Laventair Ellipta contains two active substances. 
Zdravilo Laventair Ellipta vsebuje dve učinkovini.
The results for the higher dose combination of umeclidinium bromide and vilanterol did not consistently show relevant improvements in lung function to justify its use. 
Rezultati kombinacije z večjim odmerkom umeklidinijevega bromida in vilanterola ni vedno privedla do večjega izboljšanja delovanja pljuč, zaradi česar ni mogoče upravičiti njene uporabe.
Why is Laventair Ellipta authorised in the EU? 
Zakaj je bilo zdravilo Laventair Ellipta odobreno v EU?
Laventair Ellipta also increased FEV1 by an average of 95 ml more than vilanterol alone and by 52 ml more than umeclidinium bromide alone. 
Zdravilo Laventair Ellipta je tudi povečalo vrednost FEV1 za povprečno 95 ml več kot sam vilanterol in za 52 ml več kot sam umeklidinijev bromid.
An overview of Laventair Ellipta and why it is authorised for use in the EU 
Pregled zdravila Laventair Ellipta in zakaj je odobreno v EU